NCT06271551View on ClinicalTrials.gov

Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Prostate Cancer
Interventions
DRUG

Transdermal estrogen

Participants (n=155) receiving transdermal estradiol for 12 months.

DRUG

Active Comparator: Androgen deprivation therapy

Participants (n=155) receiving solely androgen deprivation therapy for 12 months.

BEHAVIORAL

Resistance training

Participants (n=30 in each arm) performing supervised resistance training for six months.

All Listed Sponsors
collaborator

Tampere University

OTHER

collaborator

University of Jyvaskyla

OTHER

collaborator

Tampere University Hospital

OTHER

lead

Central Finland Hospital District

OTHER

NCT06271551 - Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy | Biotech Hunter | Biotech Hunter